Pulmonx Corp.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.91
- 52-Week Range
- $1.13 – $2.89
- Market Cap
- $77.29M
- P/E (TTM)
- —
- EPS (TTM)
- -1.15
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.00
- PEG Ratio
- —
- Return on Equity
- -88.87%
- Return on Assets
- -22.10%
- Gross Margin
- 77.06%
- Operating Margin
- -39.80%
- Profit Margin
- -55.03%
- Current Ratio
- 4.32
- Debt/Equity
- 1.43
- Total Debt
- $56.21M
- Free Cash Flow
- $-11.74M
- Revenue Growth
- -4.60%
- Earnings Growth
- —
- Enterprise Value
- $78.96M
Market Snapshot
About
Pulmonx Corp. is a commercial-stage medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and emphysema. The company developed the Zephyr Endobronchial Valve, a small one-way valve implanted in the airways to help severe emphysema patients breathe more easily. Their products are designed to reduce lung hyperinflation without surgery.